From Dealroom · · 30s
TL;DR: VitriVax raises $87M for Lyme vaccine
VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine.
VitriVax raised $87 million Series C to pursue Lyme disease vaccine after no approved human vaccine exists. VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine. VitriVax raised $87 million Series C to develop Lyme disease vaccine. No approved human Lyme vaccine exists, creating unmet need for new solution.
- Funding round
- Market gap
Read the story version — the same reporting as a swipeable deck of 3 cards.
